Brief: Bridgebio Oncology Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
13/04/2026 21:54
April 13 (Reuters) - BridgeBio Oncology Therapeutics Inc BBOT.O: BRIDGEBIO ONCOLOGY THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Source text: ID:nGNX2VZChW Further company coverage: BBOT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bridgebio Oncology Therapeutics
See all newsBrief: Bridgebio Oncology Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Bridgebio Oncology Therapeutics - May Offer Up To $500 Million In Securities - SEC Filing
Brief: Bridgebio Oncology Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
BridgeBio Oncology Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Bbot Reports First Quarter 2026 Financial Results And Update On Corporate Progress